Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,855 across all filing types
Latest filing 2026-03-26 Annual Report
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
549300QKJ78IY0IOV655-2025-12-31-1-nl.xhtml
Annual Report Classification · 100% confidence The document is titled 'Jaarverslag 2025' (Annual Report 2025) for Galapagos N.V. It contains comprehensive sections including a letter from the CEO and Chairman, financial highlights, sustainability disclosures, governance information, risk factors, and consolidated financial statements. It explicitly mentions being the 'Jaarverslag 2025' and provides a detailed table of contents covering the full fiscal year. It is not a short announcement (RPA) or a simple regulatory filing (RNS), but the full annual report itself. FY 2025
2026-03-26 Dutch
Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases
Regulatory Filings Classification · 85% confidence The document is a Galápagos press release labeled as "regulated information – inside information," outlining a strategic collaboration and the terms of a potential partnership with Gilead. It is not a full financial report, earnings release, or regulatory filing of a specific form (like a 10-K or IR). It does not present financial statements, a call transcript, or a detailed investor slide deck, nor is it merely announcing the publication of a separate report. It is a general corporate announcement of business development activity and therefore best fits the fallback category for miscellaneous regulatory and corporate announcements: Regulatory Filings (RNS).
2026-03-24 English
Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases
M&A Activity Classification · 75% confidence The document is a corporate press release announcing advanced talks on a strategic collaboration following Gilead’s acquisition of Ouro Medicines, including the terms of the takeover and milestone payments. This is not an earnings release, management change, dividend, or ESG report, but clearly falls under M&A-related announcements. Therefore, it should be classified as M&A Activity (TAR).
2026-03-24 Dutch
Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases.pdf
Capital/Financing Update Classification · 75% confidence The document is a regulated press release announcing Galapagos’s entry into advanced partnership discussions with Gilead following Gilead’s acquisition of Ouro Medicines. It lays out financial terms of the proposed strategic collaboration, cost‐sharing of upfront and milestone payments, use of cash resources (including exempting $500 million for share repurchases and other uses), and impact on Galapagos’s capital allocation. There are no quarterly results, no AGM agenda or voting results, and no M&A takeover by Galapagos itself—rather a collaboration/financing arrangement. This fits the “Capital/Financing Update” category.
2026-03-23 English
Galapagos en Gilead in vergevorderde gesprekken over samenwerking om een first-in-class T-cel-engagerprogramma voor auto-immuunziekten verder t.pdf
Regulatory Filings Classification · 75% confidence The document is a press release by Galápagos NV describing advanced discussions with Gilead Sciences regarding a strategic collaboration on assets acquired from Ouro Medicines. It includes deal economics, milestone payments, capital allocation, and regulatory disclaimers. There is no formal acquisition or takeover proposal by Galápagos (so it is not M&A Activity), nor is it announcing a fundraising, share issuance, dividend, or financial report. It is a regulatory announcement of corporate developments that does not neatly fit a more specific category, so it falls under the fallback category “Regulatory Filings (RNS).”
2026-03-23 Dutch
Galapagos Receives Transparency Notification from Bank of America
Major Shareholding Notification Classification · 100% confidence The document is a formal notification regarding a change in major shareholding (Bank of America falling below the 5% threshold of Galapagos' voting rights). This is a standard regulatory disclosure required under transparency legislation for publicly traded companies. It fits the definition of a 'Major Shareholding Notification' (MRQ) as it details the crossing of a specific ownership threshold.
2026-03-18 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.